drugset / Trial / NCT03636295

Low INR to Minimize Bleeding With Mechanical Valves Trial

NCT03636295

RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.

Timeline

Start
2019-09-05
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Warfarin Small molecule